Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway

Kong,Wencui; Ling,Xiaoming; Chen,Ying; Wu,Xiaoli; Zhao,Zhongquan; Wang,Wenwu; Wang,Shuiliang; Lai,Guoxiang; Yu,Zongyang

doi:10.3892/ijmm.2020.4485

Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway

Authors:
- Wencui Kong
- Xiaoming Ling
- Ying Chen
- Xiaoli Wu
- Zhongquan Zhao
- Wenwu Wang
- Shuiliang Wang
- Guoxiang Lai
- Zongyang Yu
View Affiliations

Affiliations: Department of Medical Oncology, 900 Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, P.R China, Faculty of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R China , Department of Medical Oncology, The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R China, Department of Urology, 900th Hospital of the Joint Logistics Team, Fujian Medical University, Fuzhou, Fujian 350025, P.R China, Department of Respiratory and Critical Care Medicine, 900 Hospital of the Joint Logistics Team, Fuzhou, Fujian 350025, P.R China
Published online on: February 5, 2020 https://doi.org/10.3892/ijmm.2020.4485
Pages: 1213-1224
Copyright: © Kong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑associated mortality worldwide. Cisplatin (DDP) is a first‑line chemotherapeutic drug for the treatment of lung cancer; however, the majority of patients develop resistance to DDP. P‑glycoprotein (P‑gp), also referred to as multidrug resistance (MDR) protein 1, is associated with an MDR phenotype, which results in failure of cancer chemotherapy; thus, identifying effective MDR pump inhibitors may improve the outcomes of patients who develop resistance to treatment. Hesperetin is a derivative of hesperidin, which is extracted from tangerine peel and exhibits multiple antitumor properties. In the present study, human lung adenocarcinoma A549 and A549/DDP cells were treated with different concentrations of hesperetin and DDP, respectively. Furthermore, rhodamine 123 efflux assays, Cell Counting Kit‑8 assays, immunofluorescence, reverse transcription‑quantitative PCR and western blot analysis were used to elucidate the mechanisms underlying the effects of hesperetin On A549/DDP cells. Additionally, a xenograft model of lung cancer in nude mice was established to explore the effects of hesperetin on A549/DDP cell growth in vivo. The results demonstrated that hesperetin sensitized A549/DDP cells to DDP. In vivo, hesperetin pretreatment significantly inhibited tumor growth. Mechanistically, hesperetin markedly decreased the expression of P‑gp and increased the intracellular accumulation of the P‑gp substrate, rhodamine 123, in A549/DDP cells. In addition, pretreatment of A549/DDP cells with hesperetin significantly inhibited nuclear factor (NF)‑κB (p65) activity and its nuclear translocation. Taken together, the results of the present study suggest that hesperetin reversed P‑gp‑mediated MDR by decreasing P‑gp expression in A549/DDP cells, which was associated with inhibition of the NF‑κB signaling pathway. These findings may provide the basis for the use of hesperetin clinically to reverse MDR.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Girard L, Rodriguez-Canales J, Behrens C, Thompson DM, Botros IW, Tang H, Xie Y, Rekhtman N, Travis WD, Wistuba II, et al: An expression signature as an aid to the histologic classification of non-small cell lung cancer. Clin Cancer Res. 22:4880–4889. 2016. View Article : Google Scholar : PubMed/NCBI
3	Nizzoli R, Tiseo M, Gelsomino F, Bartolotti M, Majori M, Ferrari L, De Filippo M, Rindi G, Silini EM, Guazzi A and Ardizzoni A: Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol. 6:489–493. 2011. View Article : Google Scholar : PubMed/NCBI
4	Osmani L, Askin F, Gabrielson E and Li QK: Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 52:103–109. 2018. View Article : Google Scholar
5	Watanabe SI, Nakagawa K, Suzuki K, Takamochi K, Ito H, Okami J, Aokage K, Saji H, Yoshioka H, Zenke Y, et al: Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer. Jpn J Clin Oncol. 47:1112–1118. 2017. View Article : Google Scholar : PubMed/NCBI
6	Pöttgen C, Eberhardt W, Stamatis G and Stuschke M: Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC)-a cumulative meta-analysis of the randomized evidence. Oncotarget. 8:41670–41678. 2017. View Article : Google Scholar
7	Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, et al: Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 33:3488–3515. 2015. View Article : Google Scholar : PubMed/NCBI
8	Rancoule C, Guy JB, Vallard A, Ben Mrad M, Rehailia A and Magné N: 50th anniversary of cisplatin. Bull Cancer. 104:167–176. 2017.In French. View Article : Google Scholar
9	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhang K, Wang X and Wang H: Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line. Mol Med Rep. 10:2065–2072. 2014. View Article : Google Scholar : PubMed/NCBI
11	Yao C, Jiang J, Tu Y, Ye S, Du H and Zhang Y: β-elemene reverses the drug resistance of A549/DDP lung cancer cells by activating intracellular redox system, decreasing mitochondrial membrane potential and P-glycoprotein expression, and inducing apoptosis. Thorac Cancer. 5:304–312. 2014. View Article : Google Scholar : PubMed/NCBI
12	Lv J and Tian Y: Effect of Src tyrosine kinase inhibition on the drug-resistance as well as MDR1 and LRP expression of the human cis-platinum-resistant lung cancer cell line A549/DDP. Zhongguo Fei Ai Za Zhi. 15:501–506. 2012.In Chinese. PubMed/NCBI
13	Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X, Wei C, Yang S, Wang T, Wong NJ, et al: Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun. 10:45232019. View Article : Google Scholar : PubMed/NCBI
14	Wagner L, Cramer H, Klose P, Lauche R, Gass F, Dobos G and Langhorst J: Herbal medicine for cough: A systematic review and meta-analysis. Forsch Komplementmed. 22:359–368. 2015.
15	Wong YK, Xu C, Kalesh KA, He Y, Lin Q, Wong WSF, Shen HM and Wang J: Artemisinin as an anticancer drug: Recent advances in target profiling and mechanisms of action. Med Res Rev. 37:1492–1517. 2017. View Article : Google Scholar : PubMed/NCBI
16	Safarzadeh E, Sandoghchian Shotorbani S and Baradaran B: Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull. 4(Suppl 1): 421–427. 2014.PubMed/NCBI
17	Roohbakhsh A, Parhiz H, Soltani F, Rezaee R and Iranshahi M: Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci. 124:64–74. 2015. View Article : Google Scholar : PubMed/NCBI
18	Xia R, Sheng X, Xu X, Yu C and Lu H: Hesperidin induces apoptosis and G0/G1 arrest in human non-small cell lung cancer A549 cells. Int J Mol Med. 41:464–472. 2018.
19	Xia R, Xu G, Huang Y, Sheng X, Xu X and Lu H: Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci. 201:111–120. 2018. View Article : Google Scholar : PubMed/NCBI
20	Bodduluru LN, Kasala ER, Barua CC, Karnam KC, Dahiya V and Ellutla M: Antiproliferative and antioxidant potential of hesperetin against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Chem Biol Interact. 242:345–352. 2015. View Article : Google Scholar : PubMed/NCBI
21	Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G and Devaki T: Modulatory effect of hesperidin on benzo(a)pyrene induced experimental lung carcinogenesis with reference to COX-2, MMP-2 and MMP-9. Eur J Pharmacol. 649:320–327. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kamaraj S, Anandakumar P, Jagan S, Ramakrishnan G and Devaki T: Hesperidin attenuates mitochondrial dysfunction during benzo(a)pyrene-induced lung carcinogenesis in mice. Fundam Clin Pharmacol. 25:91–98. 2011. View Article : Google Scholar
23	Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S and Devaki T: Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice. Invest New Drugs. 27:214–222. 2009. View Article : Google Scholar
24	Wolfram J, Scott B, Boom K, Shen J, Borsoi C, Suri K, Grande R, Fresta M, Celia C, Zhao Y, et al: Hesperetin liposomes for cancer therapy. Curr Drug Deliv. 13:711–719. 2016. View Article : Google Scholar
25	El Daibani AA, Xi Y, Luo L, Mei X, Zhou C, Yasuda S and Liu MC: Sulfation of hesperetin, naringenin and apigenin by the human cytosolic sulfotransferases: A comprehensive analysis. Nat Prod Res. 6:1–7. 2018. View Article : Google Scholar
26	Aranganathan S and Nalini N: Efficacy of the potential chemopreventive agent, hesperetin (citrus flavanone), on 1,2-dimethylhydrazine induced colon carcinogenesis. Food Chem Toxicol. 47:2594–2600. 2009. View Article : Google Scholar : PubMed/NCBI
27	Sivagami G, Vinothkumar R, Bernini R, Preethy CP, Riyasdeen A, Akbarsha MA, Menon VP and Nalini N: Role of hesperetin (a natural flavonoid) and its analogue on apoptosis in HT-29 human colon adenocarcinoma cell line-a comparative study. Food Chem Toxicol. 50:660–671. 2012. View Article : Google Scholar
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
29	Heist RS: First-line systemic therapy for non-small cell lung cancer. Hematol Oncol Clin North Am. 31:59–70. 2017. View Article : Google Scholar
30	Zhang XW, Liu W, Jiang HL and Mao B: Chinese herbal medicine for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Am J Chin Med. 46:923–952. 2018. View Article : Google Scholar : PubMed/NCBI
31	Li TM, Yu YH, Tsai FJ, Cheng CF, Wu YC, Ho TJ, Liu X, Tsang H, Lin TH, Liao CC, et al: Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan. J Ethnopharmacol. 213:92–100. 2018. View Article : Google Scholar
32	Byun EB, Kim HM, Song HY and Kim WS: Hesperidin structurally modified by gamma irradiation induces apoptosis in murine melanoma B16BL6 cells and inhibits both subcutaneous tumor growth and metastasis in C57BL/6 mice. Food Chem Toxicol. 127:19–30. 2019. View Article : Google Scholar : PubMed/NCBI
33	Elango R, Athinarayanan J, Subbarayan VP, Lei DKY and Alshatwi AA: Hesperetin induces an apoptosis-triggered extrinsic pathway and a p53- independent pathway in human lung cancer H522 cells. J Asian Nat Prod Res. 20:559–569. 2018. View Article : Google Scholar
34	Chen X, Wei W, Li Y, Huang J and Ci X: Hesperetin relieves cisplatin-induced acute kidney injury by mitigating oxidative stress, inflammation and apoptosis. Chem Biol Interact. 308:269–278. 2019. View Article : Google Scholar : PubMed/NCBI
35	Li Q, Miao Z, Wang R, Yang J and Zhang D: Hesperetin induces apoptosis in human glioblastoma cells via p38 MAPK activation. Nutr Cancer. Jul 11–2019.Epub ahead of print.
36	Shokri Afra H, Zangooei M, Meshkani R, Ghahremani MH, Ilbeigi D, Khedri A, Shahmohamadnejad S, Khaghani S and Nourbakhsh M: Hesperetin is a potent bioactivator that activates SIRT1-AMPK signaling pathway in HepG2 cells. J Physiol Biochem. 75:125–133. 2019. View Article : Google Scholar : PubMed/NCBI
37	Mary Lazer L, Sadhasivam B, Palaniyandi K, Muthuswamy T, Ramachandran I, Balakrishnan A, Pathak S, Narayan S and Ramalingam S: Chitosan-based nano-formulation enhances the anticancer efficacy of hesperetin. Int J Biol Macromol. 107:1988–1998. 2018. View Article : Google Scholar
38	Li WX, Chen X, Yang Y, Huang HM, Li HD, Huang C, Meng XM and Li J: Hesperitin derivative-11 suppress hepatic stellate cell activation and proliferation by targeting PTEN/AKT pathway. Toxicology. 381:75–86. 2017. View Article : Google Scholar
39	Zheng HC: The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.PubMed/NCBI
40	Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, Mazeedi MAMA, Almazyadi HAM, Kallmeyer K, Dandara C, Pepper MS, et al: The role of tumor microenvironment in chemo-resistance: To survive, keep your enemies closer. Int J Mol Sci. 18:E15862017. View Article : Google Scholar
41	Cavaco MC, Pereira C, Kreutzer B, Gouveia LF, Silva-Lima B, Brito AM and Videira M: Evading P-glycoprotein mediated-efflux chemoresistance using solid lipid nanoparticles. Eur J Pharm Biopharm. 110:76–84. 2017. View Article : Google Scholar
42	Hermawan A, Wagner E and Roidl A: Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. Oncol Rep. 35:1732–1740. 2016. View Article : Google Scholar
43	Feng Q, Yang W, Gao Z, Ruan X and Zhang Y: Up-regulation of P-gp via NF-kB activation confers protection against oxidative damage in the retinal pigment epithelium cells. Exp Eye Res. 181:367–373. 2019. View Article : Google Scholar
44	Shi Y, Wang SY, Yao M, Sai WL, Wu W, Yang JL, Cai Y, Zheng WJ and Yao DF: Chemosensitization of HepG2 cells by suppression of NF-kappaB/p65 gene transcription with specific-siRNA. World J Gastroenterol. 21:12814–12821. 2015. View Article : Google Scholar : PubMed/NCBI
45	Kim M, Cooper DD, Hayes SF and Spangrude GJ: Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood. 91:4106–4117. 1998. View Article : Google Scholar : PubMed/NCBI
46	Jancis EM, Chen HX, Carbone R, Hochberg RB and Dannies PS: Rapid stimulation of rhodamine 123 efflux from multidrug-resistant KB cells by progesterone. Biochem Pharmacol. 46:1613–1619. 1993. View Article : Google Scholar : PubMed/NCBI
47	Wang Q, Dong X, Li N, Wang Y, Guan X, Lin Y, Kang J, Zhang X, Zhang Y, Li X and Xu T: JSH-23 prevents depressive-like behaviors in mice subjected to chronic mild stress: Effects on inflammation and antioxidant defense in the hippocampus. Pharmacol Biochem Behav. 169:59–66. 2018. View Article : Google Scholar : PubMed/NCBI
48	Kumar A, Negi G and Sharma SS: JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: Effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 13:750–758. 2011. View Article : Google Scholar : PubMed/NCBI